Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted
Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing claims for a target specific tolerance induction technology, which we named reVax technology. The issued patent covers the GalCer liposome that induces regulatory Tcell (Treg) and its utilisation for immune disorders such as allergy, autoimmune disease and rejection associated with transplantation. The patent will be valid until 2025. International equivalents have also been filed in other important markets, as for example USA and AUS, which also had already granted.
The reVax technology comprises a unique and the only viable method for inducing regulatory T cell by injection of a drug. Many groups have demonstrated Tregs improve immune disorders including GvHD(graft versus host disease), the first indication which we have tackled with our new drug, RGI-2001. A challenging aspect for feasible application is to expand Tregs by a compound rather than ex vivo expansion. Our clinical trial which just initiated in US will, we believe, demonstrate its potential in human and practical application in clinic.
Mr. Haru MORITA, CEO of REGiMMUNE Corporation comments: “The entire REGiMUNE team has demonstrated an extremely high level of creativity and discipline in order to launch our technology after only a few years of development. The assignation of the patent highly values the innovative power of all employees but also provides an ideal basis for positioning the company as the technology leader within Treg induction”.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Using its reVax technology, REGiMMUNE is developing ToleroVax, which may be the first drug in the class of Treg-inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-2001 for GvHD associated with BMT(Bone marrow transplantation), RGI-3100 for type I diabetes, and RGI-1000 series for allergy. Additionally REGiMMUNE is developing its RGI-4000 series for vaccine adjuvants. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Santa Clara, California. For more information, please contact through our website.
US MEDIA CONTACT